Image

Global Radiotheranostics Market – Industry Trends and Forecast to 2031

Healthcare

Image

Global Radiotheranostics Market – Industry Trends and Forecast to 2031

  • Healthcare
  • Upcoming Report
  • Apr 2024
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Radiotheranostics Market – Industry Trends and Forecast to 2031

Market Size in USD Billion

CAGR :  % Diagram

Diagram Forecast Period 2023–2031
Diagram Market Size (Base Year) USD 5,019.20 USD Million
Diagram Market Size (Forecast Year) USD 13,316.60 USD Million
Diagram CAGR %

Major Markets Players

  • Dummy1
  • Dummy2
  • Dummy3
  • Dummy4
  • Dummy5

Global Radiotheranostics Market By radioisotope (Iodine-131, Iodine-123, Gallium-68, Lutetium-167, andOthers), Application (Oncology and Non-Oncology) – Industry Trends and Forecast to 2031.

Radiotheranostics Market Analysis and Size

Radiotheranostics agents are used primarily in nuclear medicine for both imaging (diagnosis) and therapy of various diseases, particularly cancer. The concept revolves around targeting specific receptors or molecules present in diseased tissues with a radioactive component, thereby enabling both imaging to visualize the extent and nature of the disease and therapy to treat it.

Data Bridge Market Research analyzes that the global radiotheranostics market which was USD 5019.2 million in 2023, is likely to reach up to USD 13316.6 million by 2031, and is expected to undergo a CAGR of 14.2% during the forecast period. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Report Scope and Market Segmentation

Report Metric

Details

Forecast Period

2024 to 2031

Base Year

2023

Historic Years

2022 (Customizable to 2016 - 2021)

Quantitative Units

Revenue in USD Million, Volumes in Units, and Pricing in USD

Segments Covered

Radioisotope (Iodine-131, Iodine-123, Gallium-68, Lutetium-167, and Others), Application (Oncology and Non-Oncology)

Countries Covered

U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, Israel, and Rest of Middle East and Africa

Market Players Covered

Novartis AG (Germany), Bayer AG (Germany), Telix Pharmaceuticals Limited (Australia), ITM Radiopharma (Germany), RadioMedix (U.S.), IsoTherapeutics Group, LLC (U.S.), and Q BioMed Inc. (U.S.)

Market Opportunities

  • Advancements in the technology
  • Growing research and development activities

Market Definition

Radiotheranostics is an emerging medical field that combines therapeutic and diagnostic capabilities within a single radiopharmaceutical agent. The term "radiotheranostics" is a portmanteau of "radiotherapy" and "diagnostics." In radiotheranostics, a radioactive component is incorporated into a molecular compound that selectively binds to specific receptors or molecules in diseased tissues. This allows for both imaging (diagnosis) and therapy of various diseases, particularly cancer, with high precision.

Radiotheranostics Market Dynamics

Drivers

  • Increasing Incidence of Cancer

The increasing prevalence of cancer and other diseases necessitates more effective diagnostic and therapeutic approaches. Radiotheranostics offers a targeted and personalized approach to treatment, potentially improving outcomes and reducing side effects compared to conventional therapies. With the increasing prevalence of cancer worldwide, there's a growing need for more effective and targeted treatment options and this will in turn drive the market.

  • Personalized Medicine

There is a growing recognition of the importance of personalized medicine, which aims to tailor medical treatment to the individual characteristics of each patient. Radiotheranostics aligns with this trend by enabling the delivery of targeted therapy based on the specific molecular profile of a patient's disease.  Radiotheranostics allows for a more personalized approach to cancer treatment. By using imaging techniques to identify specific molecular targets on cancer cells, physicians can tailor treatment strategies to individual patients.

Opportunities

  • Advancements in Imaging Technology

The continuous evolution of imaging modalities such as positron emission tomography (PET) and single-photon emission computed tomography (SPECT) has significantly enhanced the ability to visualize and characterize diseases at a molecular level. This has expanded the scope of radiotheranostics by enabling more accurate diagnosis and staging of diseases. Advancements in imaging technology have played a significant role in the development and application of radiotheranostics for cancer treatment. These technological advancements have enabled more precise targeting of tumors, better visualization of disease progression, and improved monitoring of treatment response.

  • Growing Research and Development Activities

Research and development (R&D) activities in the field of radiotheranostics are essential for advancing the capabilities and applications of this innovative approach to disease diagnosis and treatment. These activities encompass a wide range of efforts to develop novel radiopharmaceutical agents, optimize imaging techniques, refine therapeutic protocols, and explore new applications across different disease areas.

Restraints/Challenges

  • Regulatory Hurdles

The regulatory approval process for new radiopharmaceuticals can be complex and time-consuming. Radiotheranostic agents must undergo rigorous evaluation for safety, efficacy, and quality assurance, which may delay their clinical translation and market availability. Radiotheranostic agents are subject to regulatory approval by agencies such as the Food and Drug Administration (FDA) in the United States and the European Medicines Agency (EMA) in Europe. Obtaining approval for new radiopharmaceuticals can be a lengthy and expensive process, requiring extensive preclinical and clinical data to demonstrate safety and efficacy. Regulatory agencies may also require additional studies to establish the optimal dosage, administration route, and patient selection criteria for radiotheranostic agents.

  • Cost and Budget Constraints

Radiotheranostic procedures may be costly due to the expenses associated with radiopharmaceutical production, imaging equipment, and specialized personnel. Reimbursement policies and coverage limitations by healthcare payers may present financial barriers to patient access and healthcare provider adoption. The high cost associated with radiotheranostics can indeed pose a significant barrier to its widespread adoption and market growth. Several factors contribute to the high cost of radiotheranostic procedures, including research and development expenses, production costs, regulatory requirements, and reimbursement challenges.

This radiotheranostics market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the radiotheranostics Market contact Data Bridge Market Research for an analyst brief, our team will help you make an informed market decision to achieve market growth.

Radiotheranostics Market Scope

The radiotheranostics market is segmented on the basis of radioisotope and applications. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Radioisotope

  • Iodine-131
  •  Iodine-123
  • Gallium-68
  • Lutetium-167
  • Others

Application

  • Oncology
  • Non-Oncology

Radiotheranostics Market Regional Analysis/Insights

The radiotheranostics market is analysed and market size insights and trends are provided by country, radioisotope and application as referenced above.

The countries covered in the market report are U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, Israel, and Rest of Middle East and Africa.

North America is expected to dominate the market due to the strong base of healthcare facilities, the strong presence of major players in the market, the extraordinary healthcare infrastructure, and the large pool of people with cancer.   

Asia-Pacific is expected to witness significant growth due to the increase in government initiatives to promote healthcare, the rising health awareness among the people and growing demand for advanced medical technology for diagnosis and treatment procedures, the large population pool, and the growing demand for quality healthcare in the region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends, and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of Middle East and Africa brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs, and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Radiotheranostics Market Share Analysis

The radiotheranostics market competitive landscape provides details by competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, Global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width, and breadth, application dominance. The above data points provided are only related to the companies' focus related to the market.

Some of the major players operating in the market are:

  • Novartis AG (Germany)
  • Bayer AG (Germany)
  • Telix Pharmaceuticals Limited (Australia)
  • ITM Radiopharma (Germany)
  • RadioMedix (U.S.)
  • IsoTherapeutics Group, LLC (U.S.)
  •  Q BioMed Inc. (U.S.)


SKU-

Please fill in the below form for detailed Table of Content

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Table

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Figure

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for Infographics

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Research Methodology:

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Please fill in the below form for Research Methodology

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Customization Available:

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Please fill in the below form for Available Customization

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Get online access to the report on the World's First Market Intelligence Cloud

  • Interactive Data Analysis Dashboard
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
  • Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Request for Demo

FREQUENTLY ASK QUESTIONS

The radiotheranostics market size will be worth USD 13316.6 million by 2031.
The growth rate of the radiotheranostics market is 14.2%.
Increasing Incidence of Cancer & growing recognition of the importance of personalized medicine are the growth drivers of the radiotheranostics market.
Radioisotope and applications are the factors on which the radiotheranostics market research is based.
Major companies in the radiotheranostics market are Novartis AG (Germany), Bayer AG (Germany), Telix Pharmaceuticals Limited (Australia), ITM Radiopharma (Germany), RadioMedix (U.S.), IsoTherapeutics Group, LLC (U.S.), and Q BioMed Inc. (U.S.).
Free Sample Report

CHOOSE LICENCE TYPE

  • 7000.00
  • 4800.00
  • 3000.00
  • 8000.00
  • 12000.00

Why Choose Us

Industry Coverage

DBMR works across the globe in multiple industries which equip us with knowledge across verticals and provide our clients with insights not only from their industry but how other industries will impact their ecosystem.

Regional Coverage

Coverage of Data Bridge is not restricted to developed or emerging economies. We work across the globe covering the largest array of countries where no other market research or business consulting firm has ever conducted research; creating growth opportunities for our clients in areas which are still unknown.

Technology Coverage

In today’s world, technology drives the market sentiment, so our vision is to provide our clients insights not only for developed technologies but upcoming and disrupting technological changes throughout the product lifecycle by enabling them with unforeseen opportunities in the market which will create disruption in their industry. This leads to innovation and our clients to come out as winners.

Goal Oriented Solutions

DBMR goal is to help our clients achieve their goals through our solutions; hence we formatively create the most appropriate solutions for our client needs, saving time and efforts for them to drive their grand strategies.

Unparallel Analyst Support

Our analysts take pride in our clients’ success. Unlike others, we believe in working along our clients to achieve their goals with 24 hours analyst support determining the correct needs and inspire innovation through service.

Banner

Client Testimonials